Pharma Mar S.A.

Investor Presentation • Feb 28, 2025

Comisión Nacional del Mercado de Valores Att. Director del Área de Mercados c/ Edison núm. 4 28006 Madrid

Madrid, 28 de febrero de 2025

De conformidad con lo previsto en el artículo 227 de la Ley 6/2023, de 17 de marzo, de los Mercados de Valores y de los Servicios de Inversión, y disposiciones concordantes, ponemos en su conocimiento la siguiente

OTRA INFORMACIÓN RELEVANTE

La Sociedad remite la presentación que se expondrá en la teleconferencia organizada con analistas e inversores relativa a los resultados correspondientes al ejercicio 2024, que se celebrará hoy, viernes 28 de febrero de 2025, a las 13:30 (CET).

Para unirse a la teleconferencia, se recomienda registrarse en este enlace para recibir los números de acceso y un PIN personalizado.

Para acceder sin registro previo, utilizar los siguientes números: +34 919 01 16 44 (España), +1 646 233 4753 (EE.UU.) o +44 20 3936 2999 (Reino Unido). Número de conferencia: 883194. Además, los interesados podrán seguir la presentación en directo través de este enlace.

FY 2024 Results Presentation

Madrid, February 28th 2025

AGENDA

• 1. FINANCIAL HIGHLIGHTS
• 1. BUSSINES UPDATE
• 1. Q&A & CLOSING REMARKS

José Luis Moreno VP, Director Capital Markets and Investor Relations

AGENDA

1. FINANCIAL HIGHLIGHTS

• 1. BUSINESS UPDATE
• 1. Q&A & CLOSING REMARKS

Mª Luisa de Francia Chief Financial Officer

Main financial figures

Revenues

28.5

6.7

Zepzelca Yondelis

69%

EU Distribution API sales Royalties License

56.2

28.6

Key Financial Highlights Main figures

(€ '000)	2023	2024	Var (%)
Revenues:
Product sales	71,873	66,542	-7.4%
Licensing agreements	33,590	46,518	38.5%
Royalties	52,178	61,347	17.6%
Other	512	448	-12.5%
Total revenues	158,153	174,855	10.6%
Cost of Sales	-9,613	-8,183	-14.9%
Gross Profit	148,540	166,672	12.2%
Marketing expenses	-23,542	-22,809	-3.1%
General and administrative expenses	-18,263	-24,372	33.5%
Research and Development expenses	-99,302	-103,502	4.2%
Net impairment on financial assets	271	217	-19.9%
Other operating expenses	-12,783	-13,425	5.0%
Other results	1,252	3,687	194.5%
Operating profit	-3,827	6,468	n.a.
Net financial result	204	5,517	n.a.
Profit before tax	-3,623	11,985	n.a.
Income tax expense	4,760	14,140	n.a.
Net profit	1,137	26,125	n.a.

• R&D increased 4% to €103.5mn in 2024, related to the significant increase of the activity in both LAGOON and SaLuDo trials.
• EBITDA reached €13mn as of December 2024, compared to €2.1mn in December 2023.
• Total financial debt amounted to €47.8mn, with total cash and cash equivalents of €157mn. Total net cash position of €109mn as of December 2024.
• As of December 2024, the company has generated €6.0mn in operating cash flow, an increase of €19.5 million compared to the same period of the previous year (-€13.5mn as of December 2023).

ESG Remarkable issues during FY24

• Publication of the Non-Financial Information Consolidated Statement and Sustainability Report according to CSRD and 11/2018 Spanish Law on non-financial information and diversity.
• Approval, by the Board of Directors, of the following issues:
  • o Human Rights Policy
  • o Biodiversity Policy
  • o Sustainability Plan 2024-2026
• Net Zero Plan for the decarbonization of the company in 2050.
• Climate Risks and Opportunities Report.

AGENDA

• 1. FINANCIAL HIGHLIGHTS
• 1. BUSINESS UPDATE
• 1. Q&A & CLOSING REMARKS

Luis Mora Managing Director

Pipeline – Expanding our Expertise in Oncology

			Phase 1	Phase 2	Phase 3	Market
	Soft tissue Sarcoma	Monotherapy	nd/3rd line 2
	Ovarian cancer	+ PLD (pegylated liposomal doxorubicin)	nd/3rd line 2
	R/R Multiple Myeloma1	+ dexamethasone	rd/4th line 3
	Small cell lung cancer	Monotherapy	nd line US / other countries 2
	Small cell lung cancer maintenance	+ atezolizumab	st line maintenance 1
	Small cell lung cancer	Lurbi vs. lurbi+ irinotecan vs. topotecan or irinotecan	nd line 2		LAGOON
	Leiomyosarcoma	+ doxorubicin	st line 1	Phase IIb/III
	Small cell lung cancer	+ irinotecan	nd line 2
Ecubectedin (PM14)	Small cell lung cancer combo2	+ atezolizumab	2 nd line
	Solid tumours (basket trial)	Monotherapy
	Solid tumours	Combination trials with IO
	Soft tissue sarcoma2	Combination radiation
PM534	Solid tumours	Monotherapy
PM54	Solid tumours	Monotherapy

(1) Approved in Australia (2) IST – Investigator Sponsored Trial

Positive results from the IMforte Phase 3 clinical trial Statistically significant and clinically meaningful OS & PFS benefit

• The combination of lurbinectedin and atezolizumab demonstrated a positive, statistically significant and clinically meaningful improvement in the two primary endpoints of overall survival (OS) and progression-free survival (PFS).
• PharmaMar will submit a marketing authorization application (MAA) to the EMA in the first half of 2025 to obtain the approval in Europe.
• Jazz will also submit a supplemental New Drug Application (sNDA) to the FDA.

Lurbinectedin European Market Opportunity

Leiomyosarcoma

• SaLuDo trial (Phase IIb/II)
• 1 st line therapy in combination with doxorubicin
• End of recruitment expected 1Q26
• Longer treatment duration

SCLC – 2 nd line

• LAGOON trial
• 2 nd line therapy
• Two arms:
  • Monotherapy
  • Combo with irino
• Recruitment ended 4Q24
• Nothing approved in 2L since 1996

SCLC – 1 st line maint.

- IMforte trial.

• Combination of lurbinectedin + atezolizumab
• Longer treatment duration
• Potential to be practice-changing
• Filing 1H25

Lurbinectedin. Pathway to market in EU

Lurbinectedin: Commercial outlook

Global presence

European Union

PHM territories

• Western EU.

• Commercial agreements
• UK, Scandinavia and Eastern Europe: Inmedica Pharma

Rest of the world Partner territories

US and rest of the word

• Greece, Cyprus and Balkans: Genesis Pharma

Clinical development Key pillars for sustainable growth

	2026 2027 2025	2028
	Potential indications:
PM14 (Ecubectedina)	• Small Cell Neuroendocrine High-Grade Prostate Cancer • Combination IO on-going
PM54	Potential 2nd • generation of lurbinectedin • Good safety profile • Early signs of activity in solid tumors • Phase I/II combos & monotherapy basket trial planned	Phase III trials
PM534	• Unique / Novel tubulin inhibitor • No neurotoxicity • Early signs of activity in solid tumors • Phase I/II combos & monotherapy planned

Long-term sustainable value creation for our shareholders Driving process across our strategic pillars

Lurbinectedin Development
Fully enrolled Phase 3 trial with lurbinectedin in SCLC	Other drugs
Phase 2/3 trial with lurbinectedin in leiomyosarcoma	2 Phase 2 trials with ecubectedin enrolling	Corporate development
	PM54	Looking for in-licensing products to market
Potential lurbinectedin approvals in other countries	PM534	Outlicense
		Profitable with robust balance sheet

• 1. Q&A & CLOSING REMARKS
• 1. OPERATIONAL UPDATE 2. FINANCIAL HIGHLIGHTS

AGENDA

www.pharmamar.com